| Literature DB >> 26873346 |
Abstract
DNA-sequencing giant Illumina has formed a new company, called Grail, to develop liquid biopsies capable of spotting cancer before symptoms arise. The start-up is working on a low-cost "pan-cancer" test that can detect multiple cancer types early, which it hopes to introduce by 2019. ©2016 American Association for Cancer Research.Entities:
Mesh：
Year: 2016 PMID： 26873346 DOI： 10.1158/2159-8290.CD-NB2016-015
Source DB: PubMed Journal: Cancer Discov ISSN： 2159-8274 Impact factor: 39.397